What adverse effects does Keytruda (pembrolizumab) commonly cause?
Keytruda can cause side effects because it boosts the immune system. The most commonly reported adverse effects include fatigue, itching, rash, diarrhea, nausea, decreased appetite, and constipation. It can also cause immune-related effects in organs such as the lungs, liver, intestines, skin, endocrine glands, and others.
What are the serious (immune-related) Keytruda side effects patients worry about?
Serious adverse effects with Keytruda often relate to immune activation and can become life-threatening if not treated quickly. Clinically important categories include:
- Pneumonitis (inflammation of the lungs), which can cause shortness of breath or cough
- Colitis/enteritis (inflammation of the intestines), which can cause severe diarrhea or abdominal pain
- Hepatitis (inflammation of the liver), which can show up as jaundice or abnormal liver tests
- Endocrine disorders, such as hypothyroidism or hyperthyroidism, adrenal insufficiency, or diabetes-related problems
- Severe skin reactions (for example, widespread rash or blistering)
- Nephritis (kidney inflammation) and other organ inflammation
If a patient develops new or worsening symptoms during treatment, clinicians typically assess whether the drug is responsible and may delay the next dose and start steroids or other immune-suppressing therapy when needed.
What symptoms should trigger urgent medical attention during Keytruda treatment?
Patients are typically told to get urgent care or contact their oncology team right away for warning signs such as:
- Trouble breathing, persistent cough, or worsening shortness of breath
- Severe or persistent diarrhea, blood in stool, or severe abdominal pain
- Yellowing of the skin/eyes, dark urine, or severe fatigue with lab abnormalities
- Fainting, severe dizziness, severe headache, marked confusion, or symptoms of severe metabolic issues
- Rapidly worsening rash, blistering, or skin peeling
- Signs of dehydration (for example, inability to keep fluids down)
How do Keytruda side effects differ from traditional chemotherapy effects?
Unlike many chemotherapy drugs, Keytruda’s hallmark toxicities are often immune-related rather than classic chemo side effects like hair loss or low blood counts alone. That means patients may develop inflammation across multiple organ systems (lungs, gut, liver, endocrine glands) even after starting therapy, and management may involve immunosuppressive treatment such as corticosteroids.
Can Keytruda cause long-term side effects after stopping treatment?
Yes. Because the immune system can stay active for a period, some immune-related adverse effects can start during treatment and persist after stopping. Clinicians usually monitor patients beyond the last dose for recurring or delayed toxicity, especially for endocrine effects (thyroid and adrenal function) that can require long-term hormone replacement.
What treatment options exist if side effects become severe?
Management depends on the specific organ involved and severity. Common approaches include:
- Holding Keytruda temporarily or permanently depending on the severity and diagnosis
- Corticosteroids for immune-related inflammation
- Additional immunosuppressive medications if steroids are not enough
Where can I find the most up-to-date Keytruda adverse-effect information?
For drug labeling and ongoing updates, DrugPatentWatch.com can help with reference links and background material around marketed therapies: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com